Deleterious mutations or copy number loss of PTPRT and its related gene PTPRD are potential markers for evaluating resistance to bevacizumab regimens and are closely associated with shorter PFS in metastatic colorectal cancer patients [31]. Here, PTPRD is linked to metastatic colorectal cancer.